Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 253

1.

Nanoparticles with surface antibody against CD98 and carrying CD98 small interfering RNA reduce colitis in mice.

Xiao B, Laroui H, Viennois E, Ayyadurai S, Charania MA, Zhang Y, Zhang Z, Baker MT, Zhang B, Gewirtz AT, Merlin D.

Gastroenterology. 2014 May;146(5):1289-300.e1-19. doi: 10.1053/j.gastro.2014.01.056.

2.

Drug-loaded nanoparticles targeted to the colon with polysaccharide hydrogel reduce colitis in a mouse model.

Laroui H, Dalmasso G, Nguyen HT, Yan Y, Sitaraman SV, Merlin D.

Gastroenterology. 2010 Mar;138(3):843-53.e1-2. doi: 10.1053/j.gastro.2009.11.003.

PMID:
19909746
3.

Fab'-bearing siRNA TNFα-loaded nanoparticles targeted to colonic macrophages offer an effective therapy for experimental colitis.

Laroui H, Viennois E, Xiao B, Canup BS, Geem D, Denning TL, Merlin D.

J Control Release. 2014 Jul 28;186:41-53. doi: 10.1016/j.jconrel.2014.04.046.

4.

The tumor necrosis factor family member TNFSF14 (LIGHT) is required for resolution of intestinal inflammation in mice.

Krause P, Zahner SP, Kim G, Shaikh RB, Steinberg MW, Kronenberg M.

Gastroenterology. 2014 Jun;146(7):1752-62.e4. doi: 10.1053/j.gastro.2014.02.010.

5.

Targeting intestinal inflammation with CD98 siRNA/PEI-loaded nanoparticles.

Laroui H, Geem D, Xiao B, Viennois E, Rakhya P, Denning T, Merlin D.

Mol Ther. 2014 Jan;22(1):69-80. doi: 10.1038/mt.2013.214.

6.

Activation of epithelial CD98 glycoprotein perpetuates colonic inflammation.

Kucharzik T, Lugering A, Yan Y, Driss A, Charrier L, Sitaraman S, Merlin D.

Lab Invest. 2005 Jul;85(7):932-41.

7.

Role of metallothioneins as danger signals in the pathogenesis of colitis.

Devisscher L, Hindryckx P, Lynes MA, Waeytens A, Cuvelier C, De Vos F, Vanhove C, Vos MD, Laukens D.

J Pathol. 2014 May;233(1):89-100. doi: 10.1002/path.4330.

PMID:
24452846
8.

Chitosan oligosaccharide as potential therapy of inflammatory bowel disease: therapeutic efficacy and possible mechanisms of action.

Yousef M, Pichyangkura R, Soodvilai S, Chatsudthipong V, Muanprasat C.

Pharmacol Res. 2012 Jul;66(1):66-79. doi: 10.1016/j.phrs.2012.03.013.

PMID:
22475725
9.

TFF2 deficiency exacerbates weight loss and alters immune cell and cytokine profiles in DSS colitis, and this cannot be rescued by wild-type bone marrow.

Judd LM, Chalinor HV, Walduck A, Pavlic DI, Däbritz J, Dubeykovskaya Z, Wang TC, Menheniott TR, Giraud AS.

Am J Physiol Gastrointest Liver Physiol. 2015 Jan 1;308(1):G12-24. doi: 10.1152/ajpgi.00172.2014.

10.

Glucocorticoid-induced tumor necrosis factor receptor family-related protein regulates CD4(+)T cell-mediated colitis in mice.

Liao G, Detre C, Berger SB, Engel P, de Waal Malefyt R, Herzog RW, Bhan AK, Terhorst C.

Gastroenterology. 2012 Mar;142(3):582-591.e8. doi: 10.1053/j.gastro.2011.11.031.

11.

Gastrointestinal delivery of anti-inflammatory nanoparticles.

Laroui H, Sitaraman SV, Merlin D.

Methods Enzymol. 2012;509:101-25. doi: 10.1016/B978-0-12-391858-1.00006-X.

PMID:
22568903
12.

Oroxyloside prevents dextran sulfate sodium-induced experimental colitis in mice by inhibiting NF-κB pathway through PPARγ activation.

Wang X, Sun Y, Zhao Y, Ding Y, Zhang X, Kong L, Li Z, Guo Q, Zhao L.

Biochem Pharmacol. 2016 Apr 15;106:70-81. doi: 10.1016/j.bcp.2016.02.019.

PMID:
26947454
13.

Colonic gene silencing using siRNA-loaded calcium phosphate/PLGA nanoparticles ameliorates intestinal inflammation in vivo.

Frede A, Neuhaus B, Klopfleisch R, Walker C, Buer J, Müller W, Epple M, Westendorf AM.

J Control Release. 2016 Jan 28;222:86-96. doi: 10.1016/j.jconrel.2015.12.021.

PMID:
26699423
14.

The membrane-bound mucin Muc1 regulates T helper 17-cell responses and colitis in mice.

Nishida A, Lau CW, Zhang M, Andoh A, Shi HN, Mizoguchi E, Mizoguchi A.

Gastroenterology. 2012 Apr;142(4):865-874.e2. doi: 10.1053/j.gastro.2011.12.036.

15.

Tumor Necrosis Factor Receptor 2 Restricts the Pathogenicity of CD8(+) T Cells in Mice With Colitis.

Punit S, Dubé PE, Liu CY, Girish N, Washington MK, Polk DB.

Gastroenterology. 2015 Oct;149(4):993-1005.e2. doi: 10.1053/j.gastro.2015.06.004.

16.

Negative impact of bone-marrow-derived mesenchymal stem cells on dextran sulfate sodium-induced colitis.

Nam YS, Kim N, Im KI, Lim JY, Lee ES, Cho SG.

World J Gastroenterol. 2015 Feb 21;21(7):2030-9. doi: 10.3748/wjg.v21.i7.2030.

17.

Gene silencing of TNF-alpha in a murine model of acute colitis using a modified cyclodextrin delivery system.

McCarthy J, O'Neill MJ, Bourre L, Walsh D, Quinlan A, Hurley G, Ogier J, Shanahan F, Melgar S, Darcy R, O'Driscoll CM.

J Control Release. 2013 May 28;168(1):28-34. doi: 10.1016/j.jconrel.2013.03.004.

PMID:
23500058
18.

T cell-associated CD18 but not CD62L, ICAM-1, or PSGL-1 is required for the induction of chronic colitis.

Ostanin DV, Furr KL, Pavlick KP, Gray L, Kevil CG, Shukla D, D'Souza D, Hoffman JM, Grisham MB.

Am J Physiol Gastrointest Liver Physiol. 2007 Jun;292(6):G1706-14.

19.
20.

Novel anti-inflammatory agent 3-[(dodecylthiocarbonyl)-methyl]-glutarimide ameliorates murine models of inflammatory bowel disease.

Ichikawa N, Yamashita K, Funakoshi T, Ichihara S, Fukai M, Ogura M, Kobayashi N, Zaitsu M, Yoshida T, Shibasaki S, Koshizuka Y, Tsunetoshi Y, Sato M, Einama T, Ozaki M, Umezawa K, Suzuki T, Todo S.

Inflamm Res. 2016 Mar;65(3):245-60. doi: 10.1007/s00011-015-0911-0.

PMID:
26683259
Items per page

Supplemental Content

Support Center